XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.24.1

INCOME TAXES | 12 Months Ended
--- | ---
Dec. 31, 2023
Income Tax Disclosure [Abstract] |
INCOME TAXES | NOTE 14 — INCOME TAXES The following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the periods presented: SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS
|  | December 31, 2023 |  |  | December 31, 2022 |
Domestic |  | $ | (12,479,803 | ) |  | $ | (13,887,914 | )
Foreign |  |  | — |  |  |  | — |
Loss before provision for income taxes |  | $ | (12,479,803 | ) |  | $ | (13,887,914 | )
A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE
|  | December 31, 2023 |  |  | December 31, 2022 |
Statutory federal income tax rate |  |  | 21.00 | % |  |  | 21.00 | %
State taxes, net of federal tax benefit |  |  | 1.76 | % |  |  | 7.50 | %
Non-deductible expenses |  |  | -0.64 | % |  |  | -2.09 | %
NOL expiration |  |  | -5.26 | % |  |  | -19.88 | %
Tax credit |  |  | 2.92 | % |  |  | 3.71 | %
Goodwill impairment |  |  | 0.00 | % |  |  | 0.00 | %
Foreign rate differential |  |  | 0.00 | % |  |  | 0.00 | %
Change in fair value of warrant liability |  |  | 3.35 | % |  |  | 0.00 | %
Tax impact of convertible debenture |  |  | -5.46 | % |  |  | 1.37 | %
Tax impact of divestiture |  |  | -229.26 | % |  |  | 4.01 | %
True-up |  |  | -10.65 | % |  |  | 2.24 | %
Change in valuation allowance |  |  | 222.28 | % |  |  | -17.91 | %
Income taxes provision (benefit) |  |  | 0.04 | % |  |  | -0.05 | %
Income tax expense for the year ended December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PROVISION FOR INCOME TAXES
|  | December 31, 2023 |  |  | December 31, 2022 |
|  | For the Years Ended |
|  | December 31, 2023 |  |  | December 31, 2022 |
Current |  |  |  |  |  |  |  |
U.S. Federal |  | $ | (10,000 | ) |  | $ | — |
U.S. State |  |  | 5,000 |  |  |  | 7,000 |
Total current provision |  |  | (5,000 | ) |  |  | 7,000 |
Deferred Benefit |  |  |  |  |  |  |  |
U.S. Federal |  |  | 23,128,000 |  |  |  | (236,000 | )
U.S. State |  |  | 4,697,000 |  |  |  | (2,252,000 | )
Total deferred benefit |  |  | 27,825,000 |  |  |  | (2,488,000 | )
Change in valuation allowance |  |  | (27,825,000 | ) |  |  | 2,488,000 |
Total provision (benefit) for income taxes |  | $ | (5,000 | ) |  | $ | 7,000 |
The components of deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES
|  | December 31, 2023 |  |  | December 31, 2022 |
Deferred tax assets: |  |  |  |  |  |  |  |
Net operating loss |  | $ | 8,644,000 |  |  | $ | 32,587,000 |
Research and development credits |  |  | 4,970,000 |  |  |  | 7,857,000 |
Accrued expenses |  |  | 68,000 |  |  |  | 1,020,000 |
Patent |  |  | — |  |  |  | — |
Stock compensation |  |  | 3,004,000 |  |  |  | 3,069,000 |
Research and development expenses |  |  | 1,102,000 |  |  |  | 1,196,000 |
Fixed assets |  |  | — |  |  |  | 280,000 |
Total deferred income tax assets |  |  | 17,788,000 |  |  |  | 46,009,000 |
Deferred tax liabilities: |  |  |  |  |  |  |  |
Intangible assets |  |  | — |  |  |  | (13,000 | )
Right-of-use asset |  |  | — |  |  |  | (382,000 | )
Total deferred income tax liabilities |  |  | — |  |  |  | (395,000 | )
Net deferred income tax assets |  |  | 17,788,000 |  |  |  | 45,614,000 |
Valuation allowance |  |  | (17,788,000 | ) |  |  | (45,614,000 | )
Deferred tax asset, net of allowance |  | $ | — |  |  | $ | — |
Based on the available objective evidence, including the Company’s history of cumulative losses, management believes it is likely that the Company’s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2023 and December 31, 2022. Due to the full valuation allowance already in place on the Company’s U.S. federal and state net deferred tax assets, the Company does not anticipate significant changes in the Company’s effective tax rate. However, there is no valuation allowance recorded against the Company’s foreign net operating loss deferred tax assets, as the Company’s foreign IPR&D deferred tax liabilities and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred tax liability. The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (“R&E”) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&E expenditures that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically, costs for U.S. based R&E activities must be amortized over five years and costs for foreign R&E activities must be amortized over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2023 and 2022 consolidated financial statements, noting that the impact on the Company’s consolidated financial statements was immaterial. At December 31, 2023, the Company has U.S. federal and state net operating loss carryforwards of approximately $15,942,000 and $78,693,000, respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company’s ability to utilize its pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization limitation. The Company also has research and development credit carryforwards for federal and state tax purposes of approximately $3,560,000 and $1,410,000, respectively. The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite life for state tax purposes. U.S. income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary difference is not practicable because of the complexities of the hypothetical calculation. The Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company’s U.S. federal income tax returns remain subject to examination by the Internal Revenue Service. The Company’s California income tax returns remain subject to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination. Generally accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company’s financial statements and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company adopted these provisions effective April 1, 2009. The Company did not have any unrecognized tax benefits as of December 31, 2023 and December 31, 2022 and does not expect this to change significantly over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2023, the Company has not accrued any interest or penalties related to uncertain tax positions.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration